NCT06768840 Vitiligo, New Treatment and Serum s100B
| NCT ID | NCT06768840 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | South Valley University |
| Condition | Vitiligo, Generalized |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-10-02 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2024-10-02 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Eligibility Criteria
Inclusion Criteria: * active generalized vitiligo patients with body surface area involved \>5% excluding hands and feet * no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks. Exclusion Criteria: * acrofacial, acral, segmental or mucosal vitiligo * patients on another immunosuppressive agent * patients have other skin conditions (psoriasis, SLE, alopecia areata) that would interfere with evaluations of the effect of study medication on vitiligo. * patients who suffered from systemic diseases affecting S100B (e.g. Subarachnoid hemorrhage, Alzheimer disease and inflammatory diseases) or from other dermatological diseases affecting S100B level (e.g. malignant melanoma) * Patients immunocompromised, uncontrolled arterial hypertension, clinically serious viral, bacterial, fungal, or parasitic infection, anemia, history of thromboembolic event, cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, lymphoproliferative disease, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness. * Pregnancy and lactation.
Contact & Investigator
EMAN A OSMAN, bachelor
PRINCIPAL INVESTIGATOR
Qena university hospital, Qena faculty of medicine
Frequently Asked Questions
Who can join the NCT06768840 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 75 Years, studying Vitiligo, Generalized. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06768840 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06768840 currently recruiting?
Yes, NCT06768840 is actively recruiting participants. Contact the research team at em.ea01127@gmail.com for enrollment information.
Where is the NCT06768840 trial being conducted?
This trial is being conducted at Qina, Egypt.
Who is sponsoring the NCT06768840 clinical trial?
NCT06768840 is sponsored by South Valley University. The principal investigator is EMAN A OSMAN, bachelor at Qena university hospital, Qena faculty of medicine. The trial plans to enroll 50 participants.